Abstract
Aims. Development of optimal schemes of antihelicobacter therapy in children with chronic Hp-associated gastroduodenitis. Materials and methods. 16 600 children aged 3 to 18 years with chronic Hp-associated gastroduodenitis were examined and treated. To verify the diagnosis, endoscopic examination of the stomach and duodenum was used with sampling and further examination of biopsy material from the mucous wall of the stomach and duodenum by histological methods of staining sections with hematoxylin-eosin, impregnation with silver nitrate according to Warting-Starry, Kupriyanov, Campos (6 200 patients). A de-nol test was used to detect Hp in biopsies in 6 320 sick children, a respiratory test for Hp in 7 100 children with chronic gastroduodenitis. Results and conclusion. The optimal scheme of antihelicobacter therapy in children with chronic gastroduodenitis is currently the following combination of drugs: bismuth tricalium dicitrate + nifuratel + amoxicillin or macrolide. The high efficiency of the use of immunocorrecting drugs in the treatment of this pathology has been shown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
